Overview

A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer

Status:
Terminated
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety of erlotinib for non-small cell lung cancer patients with leptomeningeal carcinomatosis
Phase:
Phase 2
Details
Lead Sponsor:
Clinical Research Center for Solid Tumor, Korea
Collaborators:
Korean Cancer Study Group
Seoul National University Hospital
Treatments:
Erlotinib Hydrochloride